Matthew Jones is using experimental technology and computation to decode the molecular processes that underlie the way tumors evolve to resist treatment by pinpointing how and when aggressive mutations arise.

Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have found that depleting a clotting protein made by the liver could slow down pancreatic cancer.

Boron agents termed GluBs, developed by Science Tokyo researchers, have overcome a key limitation in cancer therapy by entering tumor cells through a pathway that standard drugs cannot use.

Now, researchers from the Tissue Engineering Group of the Department of Histology at the University of Granada’s Faculty of Medicine and the ibs.GRANADA Institute for Biomedical Research have created highly biocompatible, resistant, and transparent corneal implants from scales of various types of fish commonly found on the market, such as carp. The findings are published in the journal Materials & Design.

Cancer cells consume oxygen and nutrients at a higher rate than healthy tissue,. This drug delivery system senses those physical changes and guides medicine to the disease. The drug is released only when it encounters those tumor-specific conditions.